Database

Startups

Main Industry
Health Care
Main Product/Service
Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl
Founded Year
2021
Unified Business No.
90531036
Status
Active
Number of Employees
8
Total Paid-in Capital
0 (NT$)
Location of Company
Taiwan , Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, Ministry of Economic Affairs.
Introduction
Ochre Bio is a biotech company focused on chronic liver disease therapeutics, aiming to eliminate the need for liver transplants. Their platform integrates human liver data, AI‑driven genomics, and in‑house validation using perfused human liver tissue to



More2 ↓
Corporate Video

Similar Companies

TAIWAN BIO THERAPEUTICS INC.

Leveraging the FAST CGT platform to enhance the specificity, persistence, and stability of regulatory T cells, improving their ability to restore immune tolerance and suppress inflammation as a targeted alternative to non-selective, high-risk immunosuppre

GenomeFrontier Therapeutics TW Co., Ltd.

GenomeFrontier’s product pipeline is built around its Quantum Engine™, which integrates four core platforms: Quantum Nufect™ (gentle, efficient gene delivery), Quantum pBac™ (high-capacity non-viral gene integration), iCellar™ (robust cell expansion), and

法信諾生醫股份有限公司

1. COVID-19 Vaccine (V-CO)
2. Nucleic acid medicine- V-ADmir
3. Brain Delivery Platform- VBT
:::